8-K: Wellgistics Health Secures $3.125M Convertible Note Offering

Wellgistics Health, Inc. has secured a private offering of up to $3.125 million in convertible promissory notes to fund its 2026 strategic growth initiatives, focusing on AI platform integration and pharmacy network expansion.

Summary

• Wellgistics Health, Inc. entered into a Note Purchase Agreement on January 5, 2026, for a private offering of up to $3,125,000 in aggregate principal amount of convertible promissory notes.
• The notes were purchased for a cash price of $2,500,000, reflecting a 20% original issue discount.
• The notes accrue 0% simple interest per annum, with principal and interest due on the earlier of the six-month anniversary of issuance or the closing of a Qualified Financing (gross proceeds of at least $2,000,000).
• Holders can elect to convert the notes into equity securities of a Qualified Financing, with a conversion price floor of $0.08 per share of common stock.
• The company engaged Dawson James Securities, Inc. as its exclusive placement agent, paying a 6.5% cash commission ($162,500) and issuing five-year warrants to purchase common stock equal to 5% of gross proceeds.
• The company's 2026 corporate outlook focuses on integrating its EinsteinRx AI platform into pharmacy client point-of-sale systems.
• A goal has been set to onboard up to 500 pharmacies per month into the Wellgistics Pharmacy Network by year-end 2026.
• Initial EinsteinRx optimization targets the SGLT-2 drug Brenzavvy for the diabetes market, with plans to expand to GLP-1 agonist drugs and other cardiometabolic disease treatments, including Long COVID.
• The company is assessing resources for its PharmacyChain blockchain-enabled smart contracts platform to improve healthcare delivery efficiency, payer transparency, and reduce fraud.
• The notes and placement agent warrants were sold in reliance on exemptions from registration requirements under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D to accredited investors.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for ambitious growth plans in key healthcare markets, which is positive. However, the 20% original issue discount and significant placement agent fees represent a high cost of capital. The future outlook is promising but carries substantial execution risk, leading to a moderately positive sentiment.

Positives

• Secured up to $3,125,000 in capital through convertible promissory notes, providing funding for strategic initiatives.
• The notes carry a 0% interest rate, reducing immediate debt servicing costs for the company.
• Ambitious growth targets for 2026, aiming to onboard up to 500 pharmacies per month into the Wellgistics Pharmacy Network.
• Strategic focus on integrating the EinsteinRx AI platform to optimize prescription drug dispensing and patient outcomes.
• Plans to expand manufacturer relationships into high-growth markets like GLP-1 agonists (estimated $156 billion by 2030) and cardiometabolic disorders (estimated $85 billion by 2031).
• Commitment to developing the PharmacyChain blockchain platform to enhance efficiency, transparency, and reduce fraud in healthcare delivery.

Negatives

• The notes were issued at a 20% original issue discount, meaning the company received $2,500,000 for $3,125,000 in principal amount, effectively increasing the cost of capital.
• A 6.5% cash commission ($162,500) and 5% common stock purchase warrants were paid to the placement agent, further increasing the cost of the capital raise.
• The company is restricted from incurring additional borrowed money debt or issuing debt securities (other than these notes) while the aggregate principal amount remains outstanding.
• The company is restricted from granting new liens on assets, with the exception of Intellectual Property, which could limit future financing flexibility.

Risks

• The securities (notes and warrants) have not been registered under the Securities Act or state securities laws and may not be sold without an effective registration statement or an applicable exemption.
• No public market currently exists for the notes, and there is no assurance that one will ever exist, limiting liquidity for holders.
• The company's actual future results could differ materially from forward-looking statements due to various risks, including those discussed in its SEC filings, such as the Registration Statement on Form S-1.
• The notes contain numerous events of default, including payment defaults, breaches of terms, bankruptcy, default on other indebtedness, certain change of control transactions, and even changes in senior management or Nasdaq trading suspension, which could accelerate repayment at an 18% default interest rate.
• The placement agent's obligations were on a 'best efforts' basis, meaning there was no guarantee of successful placement of the full offering amount.
• The company acknowledges that it will use commercially best efforts to cure identified material weaknesses in its internal accounting controls, implying existing control deficiencies.

Future Outlook

Wellgistics Health's 2026 outlook is centered on a 'hyper-focused operational execution phase' involving the integration of its EinsteinRx AI platform into pharmacy client point-of-sale systems. The company aims to onboard up to 500 pharmacies per month into its Wellgistics Pharmacy Network by year-end 2026. Initial efforts will optimize EinsteinRx for diabetes medications like Brenzavvy, with rapid expansion planned to include GLP-1 agonist drugs and treatments for cardiometabolic diseases, including Long COVID. Concurrently, the technology team is assessing resources for the PharmacyChain blockchain platform, with updates expected soon, to enhance healthcare delivery efficiency, payer transparency, and reduce fraud.

Management Comments

• "Three months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper-focused operational execution phase."
• "In 2026 we will focus squarely on the implementation of our EinsteinRx AI platform into pharmacy client point of sale systems, onboarding and increasing the percentage of our existing 6,500+ independent pharmacy customers that convert into our official Wellgistics pharmacy network."
• "We have set a goal of reaching a Wellgistics Pharmacy Network onboarding rate of up to 500 pharmacies per month by year end 2026."
• "While SGLT-2 drug Brenzavvy for the diabetes market is the first product that we are focused on optimizing EinsteinRx for, we intend to quickly expand our branded manufacturer relationships to include other products that primarily target similar patient populations... including patients who have been prescribed GLP-1 agonist drugs and other drugs associated with cardiometabolic disease, such as Long COVID."
• "Concurrent with this onboarding optimization effort, our technology team has been working to complete its assessment of the resources required to establish PharmacyChain... We will very soon provide updates on this exciting effort that we expect will dramatically improve efficiency in the healthcare delivery market."

Industry Context

Wellgistics Health's strategic focus on AI-driven pharmacy optimization and blockchain-enabled smart contracts aligns with broader healthcare industry trends emphasizing digital transformation, efficiency improvements, and personalized patient care. The company is targeting significant and growing markets, including diabetes (projected $79 billion by 2031), GLP-1 agonists (projected $156 billion by 2030), and cardiometabolic disorders (projected $85 billion by 2031). Its efforts to streamline prescription processes and improve reimbursement transparency address long-standing pain points for pharmacies and other stakeholders in the U.S. healthcare system, particularly in combating fraud, waste, and abuse.

Comparison to Industry Standards

• The filing highlights the significant market opportunities in diabetes (estimated $48 billion in 2024, growing to $79 billion by 2031), North American GLP-1 agonist market (estimated $53 billion in 2025, growing to $156 billion by 2030), and US cardiometabolic disorders market (estimated $46 billion in 2024, growing to $85 billion by 2031).
• The company's focus on integrating AI and blockchain technology aims to address inefficiencies and improve patient outcomes, which are common goals across the health tech industry, but no specific comparable companies or their results are mentioned in the filing.

Stakeholder Impact

• Shareholders: Potential for future growth and value creation if strategic initiatives are successful, but also risk of dilution upon conversion of notes and warrants, and the cost of capital impacts shareholder value.
• Employees: Growth and expansion plans may lead to increased opportunities and stability.
• Customers (Pharmacies): Expected benefits from the EinsteinRx AI platform, including prescription optimization tools and improved patient outcomes, potentially enhancing their business operations.
• Suppliers (Manufacturers): Expansion of branded manufacturer relationships could lead to increased business opportunities.
• Creditors (Note Holders): Receive 0% interest notes with conversion options and a subsidiary guarantee, but face risks associated with the company's performance and potential for default.

Next Steps

• Optimize the onboarding process for the EinsteinRx AI platform, leveraging client feedback to improve speed of deployment and reduce process friction.
• Accelerate the pharmacy conversion marketing effort to onboard up to 500 pharmacies per month into the Wellgistics Pharmacy Network by year-end 2026.
• Expand branded manufacturer relationships to include GLP-1 agonist drugs and other products targeting cardiometabolic disease and Long COVID patients.
• Complete the assessment of resources required to establish the PharmacyChain blockchain-enabled smart contracts platform and provide updates on this effort.

Key Dates

Recommendation

The company has secured capital to fund ambitious growth initiatives in high-potential healthcare markets, which could drive future value. However, the financing comes at a significant cost (20% OID, placement fees, warrants), and the success of the strategic plans (AI integration, pharmacy network expansion, blockchain development) is subject to considerable execution risk. For existing investors, holding the stock to observe the execution of these plans and their impact on financial performance is a reasonable approach. New investors might seek more clarity on operational milestones and financial projections before committing.

Keywords

Convertible Promissory Notes, Private Offering, Capital Raise, AI Platform, EinsteinRx, Pharmacy Network, Blockchain, PharmacyChain, Healthcare Technology, Diabetes Market, GLP-1 Agonists, Cardiometabolic Disease, SEC Filing, WGRX